Daré Bioscience (NASDAQ:DARE) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a research report released on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the biotechnology company’s stock.

A number of other analysts also recently weighed in on the stock. Dawson James downgraded shares of Daré Bioscience from a buy rating to a neutral rating in a report on Tuesday, January 30th. Brookline Capital Management lowered shares of Daré Bioscience from a buy rating to a hold rating in a research report on Wednesday, April 17th.

Daré Bioscience Stock Performance

Shares of NASDAQ:DARE opened at $0.33 on Wednesday. The business has a 50 day moving average price of $0.45 and a 200 day moving average price of $0.39. Daré Bioscience has a twelve month low of $0.27 and a twelve month high of $1.06.

Daré Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $2.17 million. Research analysts forecast that Daré Bioscience will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC acquired a new stake in Daré Bioscience, Inc. (NASDAQ:DARE) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned approximately 7.37% of Daré Bioscience as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.